CVAC News and Press, CureVac N.V. From 10/02/23

2023-10-02 12:28:56 ET More on BioNTech BioNTech: Renewed COVID Focus Might Spark Potential Share Price Boost BioNTech: Not Just Another Jab In The Arm BioNTech SE (BNTX) Q2 2023 Earnings Call Transcript Updated COVID boosters to divide America Pfizer...

2023-09-29 09:07:43 ET Shares of CureVac (NASDAQ: CVAC) were down 9.1% as of 2:45 p.m. ET Thursday after a German court temporarily suspended the biopharmaceutical company's patent trial against BioNTech (NASDAQ: BNTX) . CureVac previously failed to develop a successfu...

2023-09-28 13:47:58 ET More on CureVac CureVac's CVGBM Trial: Promising Results Progress Pipeline CureVac announces resignation of science chief CureVac - Pfizer/BioNTech patent fight extends to updated COVID shots Seeking Alpha’s Quant Rating on CureV...

2023-09-28 10:00:05 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) BofA Securities: Which small cap non-earner stocks to avoid Health Care Select Sector SPDR ETF declares quarterly distribution of $0.53...

Phase 1 part of combined Phase 1/2 study assessed comprehensive series of flu vaccine candidates, featuring up to eight separate mRNA constructs per candidate Best-performing candidate providing broad antigen coverage against WHO-recommended flu strains selected for Phase 2, following positi...

2023-08-30 16:04:07 ET Summary Moderna and Pfizer/BioNTech earned more than $110 billion from their COVID vaccines, with net profit margins of more than 50%. Alnylam, Arbutus and Genevant are suing Moderna, Pfizer, and BioNTech, alleging they infringed on patents for lipid nanopar...

Initiated Phase 2 study in COVID-19 with monovalent and bivalent, modified mRNA vaccine candidates; continued execution on infectious disease development program in collaboration with GSK Initiated Phase 1 study of cancer vaccine candidate, CVGBM, for surgically resected glioblastoma; recrui...

Phase 2 study initiated at clinical sites in Australia with monovalent and bivalent mRNA COVID-19 vaccine candidates Vaccine candidates developed in collaboration with GSK within COVID-19 vaccine development program TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 1, 2023 / ...

2023-07-24 09:51:47 ET Summary CureVac's unique dual-variant mRNA approach and robust financials position it at the forefront of biopharmaceutical research and development (R&D), despite recent dips in earnings and widened operating loss. The company's cash reserves rose to &#...

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 14, 2023 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that Dr. Igor Splawski, CureVac's Chief...